Abstract
NGENLAⓇ is the first long-acting recombinant growth hormone treatment for the indication of “short statue due to growth hormone deficiency without closed epiphyses” approved in January 2022. NGENLA is a groundbreaking medicine which offers a new once-weekly treatment option for children living with growth hormone deficiency. NGENLA can help reduce the burden associated with daily growth hormone administration and improve treatment adherence. This review summarizes the characteristics, pharmacokinetic property, and data from clinical studies of NGENLA.
